Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CPN1 | P15169 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22814152 | 1.00 | — | — | |
| SCHEMBL23410806 | 0.89 | SIGMAR1 (0.46) | ALDH1A1HSD17B10MEN1KMT2AKDM4E | |
| SCHEMBL13383637 | 0.89 | GNAI3 (0.50) | ALDH1A1HSD17B10MEN1KMT2AKDM4E | |
| SCHEMBL13671477 | 0.89 | SIGMAR1 (0.42) | ALDH1A1HSD17B10MEN1KMT2AKDM4E | |
| SCHEMBL18228194 | 0.88 | — | — | |
| SCHEMBL1857524 | 0.88 | ATM (0.50) | ALDH1A1HSD17B10MEN1KMT2AKDM4E | |
| SCHEMBL6224425 | 0.88 | — | — | |
| SCHEMBL914046 | 0.88 | — | — | |
| SCHEMBL1688129 | 0.87 | CYP1A2 (0.52) | KMT2ATDP1SIGMAR1CPN1CPB2 | |
| SCHEMBL22352195 | 0.87 | BLM (0.48) | ALDH1A1HSD17B10MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947703-B2 | Phenanthridinium derivatives as DNA binding agents | UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2011-05-24 | — | — | US | claimed |
| US-20070249652-A1 | Phenanthridinium Derivatives as Dna Binding Agents | UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2007-10-25 | — | — | US | claimed |
| EP-1692130-B1 | PHENANTHRIDINIUM DERIVATIVES AS DNA BINDING AGENTS | UNIV GLASGOW (GB) | 2007-08-08 | — | — | EP | claimed |
| EP-1692130-A2 | PHENANTHRIDINIUM DERIVATIVES AS DNA BINDING AGENTS | University Court of The University of Glasgow (GB) | 2006-08-23 | — | — | EP | claimed |
| WO-2005054241-A2 | PHENANTHRIDINIUM DERIVATIVES AS DNA BINDING AGENTS | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2005-06-16 | — | — | WO | claimed |
| US-20160317623-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2016-11-03 | — | — | US | disclosed |
| WO-2015095406-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-06-25 | — | — | WO | disclosed |
| US-7947703-B2 | Phenanthridinium derivatives as DNA binding agents | UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2011-05-24 | — | — | US | disclosed |
| US-20070249652-A1 | Phenanthridinium Derivatives as Dna Binding Agents | UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2007-10-25 | — | — | US | disclosed |
| EP-1692130-B1 | PHENANTHRIDINIUM DERIVATIVES AS DNA BINDING AGENTS | UNIV GLASGOW (GB) | 2007-08-08 | — | — | EP | disclosed |
| EP-1692130-A2 | PHENANTHRIDINIUM DERIVATIVES AS DNA BINDING AGENTS | University Court of The University of Glasgow (GB) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005054241-A2 | PHENANTHRIDINIUM DERIVATIVES AS DNA BINDING AGENTS | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317623-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | ALDH1A1 4240/4885HSD17B10 3708/4885MEN1 25/4885 |
| US-20070249652-A1 | Phenanthridinium Derivatives as Dna Binding Agents | DNA2, DDB1, TOP2B | ALDH1A1 1449/4885HSD17B10 2492/4885MEN1 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.